Cita APA

Paul, C., Griffiths, C., van de Kerkhof, P., Puig, L., Dutronc, Y., Henneges, C., . . . Reich, K. (2019). Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.

Citación estilo Chicago

Paul, C., CEM Griffiths, PCM van de Kerkhof, L. Puig, Y. Dutronc, C. Henneges, M. Dossenbach, K. Hollister, y K. Reich. Ixekizumab Provides Superior Efficacy Compared With Ustekinumab Over 52 Weeks of Treatment: Results From IXORA-S, a Phase 3 Study. 2019.

Cita MLA

Paul, C., et al. Ixekizumab Provides Superior Efficacy Compared With Ustekinumab Over 52 Weeks of Treatment: Results From IXORA-S, a Phase 3 Study. 2019.